A structure-guided approach to noncoding variant evaluation for transcription factor binding using AlphaFold 3
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkaf1417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Lukas Gerasimavicius und 2 weiteren Autor:innen. Beteiligte Einrichtung: MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, United Kingdom. Hauptthemen laut MEDLINE: Transcription Factors, Polymorphism, Single Nucleotide, DNA, Software. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Horizon 2020, Medical Research Council.
Abstract (Originalsprache)
Noncoding single-nucleotide variants (SNVs) that alter transcription factor (TF) binding can affect gene expression and contribute to disease. Sequence-based methods can excel at predicting TF binding, but rely on training data and can exhibit TF-specific biases. Here, we propose a structure-guided approach for noncoding SNVs, using AlphaFold 3 (AF3) to model TF–DNA complexes and FoldX for downstream physics-based assessment. Benchmarked against single nucleotide polymorphism-systematic evolution of ligands by exponential enrichment (SNP-SELEX) data for six TFs (SPIB, ELK3, ETV4, SF-1, PAX5, and MEIS2), the FoldX-based strategy showed good agreement with experimental allele preferences. Interestingly, differences in AF3’s interface-predicted template modelling (ipTM) score aligned even more closely with SNP-SELEX results, generally surpassing energy-based metrics. Application to known disease-associated variants recapitulated most reported effects for TFs including NKX2-5, GATA3, and USF2A-USF1. In these examples, considering both ΔipTM and FoldX energies proved more reliable than either metric alone. While less accurate than state-of-the-art sequence-based methods, this work demonstrates that structural modelling can yield interpretable insights into how noncoding variants influence TF binding. By highlighting both the promise and limitations of AF3 in this context, our study provides a framework for complementary structural evaluation of regulatory variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, United Kingdom.
- NHS Lothian, Edinburgh, EH4 2XU, United Kingdom.
ORCID-Profile: Simon C Biddie, Joseph A Marsh
Förderung
- European Research Council
- Horizon 2020
- Medical Research Council
- University of Edinburgh Read & Publish
Zitieren
APA
Gerasimavicius, L., Biddie, S. C., & Marsh, J. A. (2026). A structure-guided approach to noncoding variant evaluation for transcription factor binding using AlphaFold 3. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1417
Vancouver
Gerasimavicius L, Biddie SC, Marsh JA. A structure-guided approach to noncoding variant evaluation for transcription factor binding using AlphaFold 3. Nucleic Acids Research. 2026. doi:10.1093/nar/gkaf1417
BibTeX
@article{Gerasimavicius2026,
author = {Gerasimavicius, Lukas and Biddie, Simon C and Marsh, Joseph A},
title = {A structure-guided approach to noncoding variant evaluation for transcription factor binding using AlphaFold 3},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkaf1417}
}
EUVIMED